News

To our knowledge, CONTACT-02 is the first phase 3 study of a tyrosine kinase inhibitor-immune checkpoint inhibitor combination to show a significant improvement in progression-free survival in ...
A storm survey conducted by the National Weather Service confirms winds from an EF-1 tornado are what brought down the trees ...
During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell ...
A storm survey conducted by the National Weather Service confirms winds from an EF-1 tornado are what brought down the trees ...
Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.
The Razr+ 2025's displays are one of the areas where the phone does an obvious balancing act between the 'entry-level' Razr ...
Despite a robust cash position, Revolution Medicines' high burn rate and lofty valuation increase risk and sensitivity to ...
The company is positioning BE-Smart for near-term commercialization, targeting the $10 billion esophageal disease testing market. With dual compatibility across standard biopsy methods, BE-Smart is ...
EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- USA ...
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA ...